文献速递食管胃疾病与幽门螺杆菌消化道肿瘤与早癌消化内镜

幽门螺杆菌根除对异时性胃癌预防效果的随机对照试验

Effects of Helicobacter pylori eradication for metachronous gastric cancer prevention: a randomized controlled trial.
PubMed 文献 · Gastrointest Endosc · 2018-05-22

该开放标签、前瞻性随机对照试验在韩国首尔一家三级医院纳入898例因胃异时性病变接受内镜切除的幽门螺杆菌感染患者,比较根除治疗与不治疗对异时性胃癌发生率的影响。中位随访71.6个月,根除组异时性胃癌发生率4.1%显著低于对照组8.2%(P=0.01),校正后对照组风险比为2.02(95%CI 1.14-3.56,P=0.02)。结论认为根除幽门螺杆菌可显著降低内镜切除后异时性胃癌发生率,应考虑用于幽门螺杆菌阳性的胃肿瘤内镜切除患者。

要点

  • 根除幽门螺杆菌可显著降低内镜切除后异时性胃癌发生率(4.1% vs 8.2%,P=0.01)。
  • 对照组发生异时性胃癌的校正风险比为2.02(95%CI 1.14-3.56,P=0.02)。
  • 根除治疗在分配后5年时显示出显著差异(P=0.02)。

核心结论

  • 根除幽门螺杆菌可显著降低胃肿瘤内镜切除后异时性胃癌的发生率,应考虑用于幽门螺杆菌阳性的胃肿瘤内镜切除患者。

研究设计与样本

  • 开放标签、前瞻性随机对照试验,在韩国首尔一家三级医院开展,2005年4月至2011年2月招募,随访至2016年12月。
  • 共纳入898例因胃异时性病变接受内镜切除的幽门螺杆菌感染患者,随机分为根除组(n=442)和对照组(n=456)。
  • 根除组口服奥美拉唑20mg、阿莫西林1g、克拉霉素500mg,每日两次,疗程一周;对照组不接受幽门螺杆菌治疗。
  • 主要结局为异时性胃癌发生率,采用意向性分析。
  • 877例至少接受一次随访检查的患者纳入分析(根除组437例,对照组440例)。

主要发现

  • 中位随访71.6个月(四分位距42.1-90.0)。
  • 根除组18例(4.1%)发生异时性胃癌,对照组36例(8.2%)发生异时性胃癌(log-rank检验,P=0.01)。
  • 逐年分析显示,根除治疗在分配后5年时效应出现显著差异(log-rank检验,P=0.02)。
  • 与根除组相比,对照组发生异时性胃癌的校正风险比为2.02(95%CI 1.14-3.56,P=0.02)。

临床怎么用

  • 作者认为,幽门螺杆菌阳性的胃肿瘤患者接受内镜切除后,应考虑进行幽门螺杆菌根除治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Whether eradication of Helicobacter pylori reduces the incidence of metachronous gastric cancer (MGC) is still debatable. We aimed to evaluate the long-term effect of H pylori eradication on the development of MGC after endoscopic gastric tumor resection. METHODS: We undertook an open-label, prospective, randomized controlled trial at a tertiary hospital in Seoul, Korea. Participants were recruited during April 2005 to February 2011 and followed until December 2016. We assigned 898 patients with H pylori infection treated with endoscopic resection (ER) for gastric dysplasia or early gastric cancer to receive (n =442) or not receive (n =456) eradication therapy using a random-number chart. Eradication group patients received oral omeprazole 20 mg, amoxicillin 1 g, and clarithromycin 500 mg twice daily for a week, whereas control group patients received no H pylori treatment. The primary outcome was the incidence of MGC (intention-to-treat analysis). RESULTS: The 877 patients who attended ≥1 follow-up examination (eradication group, 437; control group, 440) were analyzed. Median follow-up was 71.6 months (interquartile range, 42.1-90.0). MGC developed in 18 (4.1%) eradication and 36 (8.2%) control group patients (log-rank test, P = .01). In our yearly analysis, the effect of eradication showed a significant difference in 5 years after allocation (log-rank test, P = .02). The adjusted hazard ratio for the control group was 2.02 (95% CI, 1.14-3.56; P = .02), compared with the eradication group. CONCLUSIONS: H pylori eradication significantly reduces the incidence of MGC after ER of gastric tumors and should be considered for H pylori-positive gastric tumor patients treated with ER. (Clinical trial registration number: NCT01510730.).

来源:Gastrointest Endosc,查看原文。版权归原作者所有。

引用

  1. Choi JM, Kim SG, Choi J, et al. Effects of Helicobacter pylori eradication for metachronous gastric cancer prevention: a randomized controlled trial. Gastrointest Endosc. 2018. PMID: 29800546. doi:10.1016/j.gie.2018.05.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。